Abstract Pluripotent and multipotent cells become increasingly lineage restricted through differentiation. Alterations to the cellular proteoglycan composition and structure should accompany these changes to influence cell proliferation, delineation of tissues and acquisition of cell migration capabilities. Retinoic acid plays an important role in pre-patterning of the early embryo. Retinoic acid can be used in vitro to induce differentiation, causing pluripotent and multipotent cells to become increasingly lineage restricted. We examined retinoic acid-induced changes in the cellular proteoglycan composition of the well-characterized teratocarcinoma line NCCIT. Our analysis revealed changes in the abundance of transcripts for genes encoding core proteins, enzymes that are responsible for early and late linkage region biosynthesis, as well as enzymes for GAG chain extension and modification. Transcript levels for genes encoding core proteins used as backbones for polysaccharide synthesis revealed highly significant increases in expression of lumican and decorin, 1,500- Glycoconj J (2013) 30:497-510 DOI 10.1007 fold and 2,800-fold, respectively. Similarly, glypican 3, glypican 5, versican and glypican 6 showed increases between 5 and 70-fold. Significant decreases in biglycan, serglycin, glypican 4, aggrecan, neurocan, CD74 and glypican 1 were observed. Disaccharide analysis of the glycans in heparin/heparan sulfate and chondroitin/dermatan sulfate revealed retinoic acid-induced changes restricted to chondroitin/dermatan sulfate glycans. Our study provides the first detailed analysis of changes in the glycosaminoglycan profile of human pluripotent cells upon treatment with the retinoic acid morphogen.
Introduction
New strategies in medical therapies, such as induced differentiation of cancer cells to block metastasis, require the ability to redirect cell behavior. In addition, optimizing the efficacy of cell-based therapies in a multicellular environment will require an understanding of how the cellular glycome can respond. In disease states, an inappropriate glycome may also provide abnormal cellular capabilities for a given tissue environment by facilitating new signaling pathways. Systematic analysis can help to provide a database of responses that can predict cellular outcomes.
The tissue multicellular environment is complex, requiring internal epigenome, transcriptome and proteome changes that are coordinated to remodel the extracellular glycome. Glycosaminoglycans (GAGs) localize mainly to the external membrane of cells and reside within the extracellular matrix. They are attached to core proteins to form cellular proteoglycans (PGs) that are critical for a variety of cell signaling and migration roles as well as mammalian organ development [1, 2] . GAGs therefore act as molecular co-receptors in cell signaling for cell-cell interactions and as regulators of cell adhesion, cell growth and differentiation [2, 3] . By defining temporal changes in GAG profiles on cells during cellular quiescence, proliferation, and lineage differentiation, we refine our global view of development in the multicellular environment. This is particularly critical for novel therapeutic applications with stem cells or tissue progenitors as well as efforts to optimize the in vitro stem cell niche for cell, tissue and organ based therapies [2, 3] .
Teratocarcinomas are malignant germ cell tumors consisting of embryonal carcinoma (EC) cells. They are malignant equivalents of normal pluripotent embryonic cells from the pre-implantation stage of embryos [4, 5] . Single embryonal carcinoma cells from teratocarcinomas develop into tumors that contain a mixed population of more than two dozen well-differentiated adult tissues from all three germ layers, including brain, muscle, bone, teeth, bone marrow, eyes, secretory glands, skin and intestine, as well as placental and yolk sac tissue. The ability of in vitro cultured embryonal carcinoma cells to form organized structures that resemble the developing embryo has promoted their use as a model system for the study of early embryonic development [6] . The widely studied NCCIT cell line, derived from a mediastinal mixed germ cell tumor, has been shown to differentiate into derivatives of all three embryonic germ layers (ectoderm, mesoderm, and endoderm) and extraembryonic cell lineages [7] . The NCCIT line is responsive to retinoic acid (RA), inducing cellular differentiation accompanied by the disappearance of oligosaccharide surface antigens associated with pluripotency [8] . For these reasons, coupled with their ease of manipulation, NCCIT cells are a useful model to quantify the concomitant changes to the glycan profile upon RA treatment to reveal promotive and/ or restrictive changes associated with the action of this morphogen for inducing loss of pluripotency and increased lineage restriction.
The biosynthetic pathways and enzymes involved in GAG biosynthesis are well defined and the enzymes and their isoforms have been found to be differentially expressed in various cell types [9] [10] [11] [12] . GAGs are linear, sulfated and highly charged heterogeneous polysaccharides consisting of a repeating disaccharide unit. Polysaccharide length and fine structure, in addition to the placement of protein-binding domains, are critical to the functioning of PGs in cell signaling. Four distinct types of GAGs are present in eukaryotic cells: chondroitin sulfate/dermatan sulfate (CS/DS), heparin/heparan sulfate (HP/HS), keratan sulfate, and hyaluronan. Modification of GAG profiles with RA treatment to induce the loss of pluripotency and lineage commitment has not been previously studied. Such information on a wellstudied morphogen is vital to obtain a more complete understanding of the underlying cellular signaling pathways that are immediately affected. As such, the NCCIT cell line affords an important model to discern GAG changes accompanying pluripotency loss and commitment to multi-lineage differentiation. In the current study, we have analyzed changes to the pluripotent cellular glycome that resulted from RA-induced differentiation. Changes in gene transcript and protein abundance for GAG biosynthesis pathways were quantified and examined using qRT-PCR and Western analysis, respectively. Disaccharide compositional analysis, utilizing liquid chromatography/mass spectrometry (LC/MS), was used to determine changes in GAG chain modifications for CS/DS and HP/HS pathways in response to RA-induced differentiation and concurrent loss of pluripotency.
Results
Changes in cell population upon RA treatment NCCIT teratocarcinoma cells were treated with RA (10 μM) for up to 40 days to induce differentiation. As observed previously with RA treatment [8] , growth of NCCIT cells slow in response, (Fig. 1a) and differentiation follows. NCCIT cells are known to undergo multilineage differentiation upon treatment with RA [8, [13] [14] [15] . Expression of markers for pluripotency, along with lineage-specific markers were monitored using qRT-PCR (Table 1 and Supplemental Table 1 ) and western blot (data not shown). In addition, immunofluorescence (Fig. 2 ) was used to monitor differentiation towards neuronal and glial lineages. Samples for qRT-PCR were taken at days 0, 14, 21, 29 and 40 days of RA treatment. Results for qRT-PCR reported are from day 40 of RA treatment. The rounded morphology of EC cells is altered drastically upon differentiation (Fig. 1b) . We observed flattened cells, including some with branched elongated cytoplasmic processes typical of neuronal morphology. Changes in morphology were accompanied by reduced expression of Oct-3/4 (3-fold) (Fig. 2 and Table 1) , which has been shown to be a pluripotency marker [3] . The expression of Nestin, a marker for neural differentiation [16] , increased 3-fold suggesting proliferation of neural progenitor cells. There were no changes in expression of beta-III-tubulin (mature neuronal marker) or Olig2 (oligodendrocyte marker) observed, whereas expression of glial fibrillary acidic protein (GFAP), a type III intermediate filament protein common to cells of the central nervous system (particularly astrocytes) was not detected. Expression of keratin associated protein 3-2 remained unchanged. Expression of an example marker of mesodermal origin RET9 decreased 6-fold. Expression of MYH6 was low at the beginning of the treatment and was not detectable later during differentiation. Expression of markers for endodermal lineages such as PDX1 increased 2-fold with no change in expression of AFP. The most dramatic increase was observed in expression of PITX2 (ectodermal marker) and HOXA5 (endodermal marker), 25-and 14,000-fold respectively. Our analysis indicates that RA treatment was redirecting cells from pluripotency and allowing for multiple differentiation pathways to execute. NCCIT cells treated in RA for 20 days were used for transcript analysis of GAG biosynthetic enzymes, as complete loss of pluripotency was observed at this point.
Changes in expression of core proteins carrying GAG chains upon RA treatment
The transcript abundance of genes encoding GAG core proteins were examined in RA-treated (day 20) versus untreated control NCCIT cells and fold-change determined (Table 2 and Fig. 3a) . Levels of selected core proteins were also examined using Western blot analysis (Fig. 3b) . The transcript levels for core proteins for CS/DS were examined, revealing that lumican (1,500-fold) and decorin (2,800-fold) increased, while fibromodulin, procollagen and versican showed no change in transcript level. Decreased expression of transcripts for CS/DS included biglycan (48-fold), aggrecan and neurocan (each 10-fold) as well as neuroglycan, bamacan, brevican, thrombomodulin, epican (CD44) and macrophage migration inhibitory factor (CD74) (range of 2-8 fold). Expression level of HS core proteins changed in RA-treated NCCIT cells in comparison to untreated NCCIT cells. In RA-treated NCCIT cells, elevated message levels for glypican 5 (68-fold), glypican 3 (12-fold) and glypican 6 (8-fold) were observed. No change in expression for agrin, syndecan 1, syndecan-2 or syndecan 4 was detected. Significant reductions in serglycin (17-fold) and glypican 4 (21-fold) messages were observed, as well as minor reductions (range of 2-6 fold) for perlecan, syndecan 3, glypican 1 and glypican 2. We next examined core proteins to determine if the magnitude of changes in their transcript levels corresponded to a concomitant increase in their expressed protein levels. Western blotting analysis (Fig. 3b ) demonstrated the most dramatic changes for expression of lumican, decorin and glypican-5. Lumican and decorin, which each displayed thousand-fold increases in transcript levels, were of particular interest. Immunoblotting confirmed a steady-state increase in protein levels for production of lumican and decorin in RA-treated NCCIT cells. In contrast, expression of glypican-5 fluctuated throughout the course of RA treatment, decreasing at day 4 and day 15 of the treatment and increasing at day 9. Biglycan proteins remained at an undetectable level in pluripotent NCCIT cells and RA treated cells (Fig. 3b) . Recombinant human biglycan was used as a positive control to confirm that the Western had worked, and that the negative results observed were reliable (data not shown).
RA effects on expression levels of enzymes involved in linkage region biosynthesis and chain extension Pathways for early and late enzymatic reactions leading to the synthesis of CS/DS and HP/HS GAG chains were examined. Early stage biosynthesis of both CS/DS and HP/HS occurs by initialization of GAG chains on core proteins within shared and distinct branched pathways (Fig. 4a) . Several genes encode enzymes that regulate the early steps of CS/DS and HP/ HS biosynthesis. These include xylosyl transferases (XYLT1 and XYLT2), β4-galactosyltransferase (β4GALT7), β3-g a l a c t o s y l t r a n s f e r a s e ( β 3 G A L T 6 ) , a n d β 3 -glucuronosyltransferase (β3GAT3). The biosynthesis of CS/ DS and HP/HS diverge in the chain extension and modification steps. For HP/HS linkage region biosynthesis and chain extension, α-N-acetylglucosaminyltransferases (EXTL2, EXTL3), α-N-acetylglucosaminyl-β-glucuronosyl transferases (EXT1, EXT2), and the combined action of the enzymes EXT1/EXT2, EXTL1, and EXTL3 are required. CS/ DS linkage region biosynthesis and extension is committed by the activity of β-4-N-acetylgalactosamine transferases (CSGALNACTs) and chondroitin synthases (CHSY1, CHPF1, CHPF2, CHSY3). Relative transcript abundance was examined as a function of β-actin change (RA/Control, untreated) ( Table 3 and Fig. 4b ). Essentially no significant changes were observed in expression levels of enzymes involved in the common linkage region sequences. In the HP/HS pathway, only EXTL1 displayed a large change in expression, decreasing approximately 19-fold in RA-treated cells. A small, but statistically significant change in EXT2 (~2-fold) was detected, but no changes were detected in the levels of EXT1, EXTL2, or EXTL3. Examination of the expression of genes encoding the enzymes involved in the linkage region synthesis, chain initiation and extension of CS/DS revealed an approximate 8-fold decrease in transcript level of CSGAL-NACT1 in RA-treated cells. Limited (2-fold) changes in CHSY1, CHPF1, CHSY3 and CHPF2 were observed, and modest changes in transcript levels of dermatan sulfate epimerase (DSE1 and DSE2), which converts glucuronic acid (Table 4 and Fig. 5b ). Of the four isoforms of NDST, the levels of NDST3 and NDST4 transcripts increased 8-fold and 4-fold, respectively. Transcript levels for GLCE, HS2ST1, HS6ST1 and HS6ST2 isoforms, and HS3ST1 increased slightly (<5-fold) in RA-treated cells. However, a large increase in transcript abundance of~20-fold was detected for the HS6ST3 isoform following treatment with RA. Transcripts for HS3ST3B1, HS3ST4 and HS3ST5 isoforms decreased marginally in RA treated cells. In contrast, RA treatment resulted in fewer changes to transcript levels of genes involved in the modification of CS/DS GAG repeating units (Table 5 and Our knowledge of the biological functions of core proteins remains in its infancy. However, it is known that these proteins are of great interest in growth regulation, cell attachment, cellcell interaction and cell motility [17, 18] . In the CS/DS PG core proteins, RA-induced differentiation of NCCIT resulted in a dramatic increase in transcript and protein levels for the decorin core protein. Decorin plays a role in axon formation and can also suppress the expression of inhibitory CS PGs such as neurocan, brevican, phosphacan and NG2 to promote axonal growth [19, 20] . The ability to suppress inhibitory pathways for differentiation while initiating or promoting differentiation suggests dual roles for remodeling. In cancer, low levels of decorin are associated with poor prognosis and large tumor size [21] . Biglycan has been shown to have inhibitory effects on axonal growth [22] and on the growth of pancreatic cancer cell lines through G1-phase cell cycle arrest [23] . We observed a decrease in biglycan transcript level concomitant with increased decorin. However, biglycan protein expression was not detected at any time point. That could suggest that the baseline quantity of protein is low, which makes detection upon differentiation challenging. Lumican expression increased as a result of RA treatment and has been shown to play a role in slowing the growth of retinal cells of neural epithelial origin. Its high expression may therefore facilitate differentiation through cell cycle changes. Similar to decorin in breast cancer, low levels of lumican are associated with poor prognosis with large tumor size, negative estrogen receptor and progesterone receptor status and increased inflammatory response [21] . Although not as dramatic as the changes in HSPG core proteins, we observed increased glypican 5 transcript levels upon differentiation. However the increased transcript level did not seem to affect protein expression, as glypican-5 expression fluctuated throughout the RA treatment period with a final decrease observed on day 15 of the treatment. Glypicans are thought to play an important role in development and differentiation through the interaction with growth factors and morphogens [24] . Overexpression of glypican 5 increases cell proliferation by potentiating basic fibroblast growth factor (FGF), hepatocyte growth factor and Wnt1A, resulting in mesodermal inducing effects [25] . Glypican 5 is expressed in adult brain tissue localized in neurons as well as in fetal brain, lung and liver tissues. Glypican 3 was also overexpressed in RA induced differentiated NCCIT cells and has been implicated in cancers by providing FGF and bone morphogenic protein-7, as well as stimulating Wnt signaling in hepatocarcinomas [26] . It also inhibits hepatomas and is silenced in mesotheliomas and ovarian and breast cancers [27, 28] . Glypican 3 may exhibit these effects through its HS chains [29] or core protein [27, 30] . Chain composition and length are known to be important effectors of cell signaling through mediation of interactions of various growth factors and chemokines. Upon loss of pluripotency by RA treatment, we observed several changes in the transcript abundances of NCCIT genes encoding enzymes involved in early to late linkage region biosynthesis and chain extension. For CS/DS and HP/HS chain initiation and elongation following differentiation, we observed overall no dramatic changes in transcript abundance. Two exceptions to this are EXTL1 and CSGALNACT1, which play roles in chain elongation of HS and CS/DS respectively, both of which showed changes in message levels. HS chain modification enzymes function as multiple tissue-specific isoforms, which are responsible for the heterogeneous structure of HS. We found that isoforms coded by NDST3 and NDST4 were upregulated. These isoforms have been shown to be expressed during embryonal development, and it has been suggested that NDST3 may play a role in development of brain, liver, kidney and heart. Both isozymes have restricted distribution in adult organisms. In the adult mouse, NDST3 is found in the brain and heart. A small amount of NDST4 is found in brain tissue [31] [32] [33] . C5-Epimerase (GLCE) and HS2ST1 are thought to work in concert to produce HP, an oversulfated variant of HS found in mast cells. HP uses serglycin as a core 
a Fold change of transcript abundance for NCCIT-RA compared to untreated NCCIT cells. A fold change <1 indicates that the transcript is more abundant in the control cells than in the RA-treated population and a fold change >1 indicates that the transcript is more abundant in the treated cells than in the controls. A fold change equals to 1 indicates no changes in the transcript level upon RA treatment protein. Following differentiation, the transcript levels for GLCE and HS2ST1 increased only slightly and transcripts for serglycin declined. This indicates that overall HP production does not change during treatment of NCCIT cells with RA. HS6ST3 is the only one of the three isoforms of the 6-Osulfotranferases that had an ample increase in transcript abundance following RA treatment. It has broad tissue distribution, but its sub-specificity is not well understood [34] . Only slight changes in HS3ST isoform transcript levels were observed. The HS3ST isoforms generate subtle modifications in HS structure resulting in the formation of recurring pentasaccharide patterns in the chain structure characteristic of HP. This pentasaccharide sequence is the source of the anticoagulant activity of HP. Even though transcripts for all of the sulfotransferases were detected in NCCIT cells during their differentiation, disaccharide compositions of HS chains were primarily non-sulfated and showed little complexity. Taken together, our findings suggest that transcripts of the enzymes involved in HP/HS and CS/DS biosynthesis are produced at a steady-state level. The fluctuation in factors such as the level of transcripts encoding core proteins does not carry over into cell-associated GAG structural changes. The same disaccharide composition was observed throughout the entire treatment and is consistent with the lack of change in the transcript levels for the majority of HP/HS biosynthetic enzymes. Transcript abundance of the gene encoding the CS/DS chain modification enzyme GalNac4S-6ST dropped upon differentiation, even though disaccharide analyses revealed a slight increase in 4S6S structural disaccharides in CS/DS glycans. This result could be explained by our focus upon cell-associated CS/DS chains, whereas some portion of GAG chains are associated with core proteins that get secreted into the media. This result could also suggest that other factors or pathways may contribute to this structural profile at the glycome level. Our analysis of HP/HS and CS/DS disaccharides in the teratocarcinoma line NCCIT indicates significant changes occur in biosynthesis of specific core proteins of CS/DS and HSPGs. This may in part reflect neuronal commitment, which occurred in a subpopulation of our cells and which has been shown to involve these changes. However, the detected changes in actual disaccharide composition of CS/DS and HS/HP were insignificant. The HP/HS and CS/ DS GAGs examined here are known to be important in many signaling pathways such as FGF, Wnt, BMP, and Hedgehog [3, 35, 36] . Since cell-associated GAG was the only form analyzed in this study, in future experiments it would worth analyzing the structure and composition of GAG chains from PGs that are secreted into the media. This study did not examine whether changes in hyaluronic acid and keratan sulfate composition might also contribute to RAinduced morphogen effects on differentiation of NCCIT cells. Keratan sulfate has specific distribution, found in such tissues as the cornea and cartilage. However, not much is known about its role in cell development [37, 38] . Hyaluronan has been shown to be important in morphogenesis via its physical properties as well as through signaling pathways including Multiple names for an enzymatic step are tissue specific isoforms CD44. Hyaluronan is crucial in early morphogenesis of the prostate and kidney and in formation and modeling of blood vessels [39, 40] . The contribution of hyaluronan and keratan sulfate remains to be determined in future studies.
In summary, our analysis of GAG profiles of pluripotent NCCIT and RA-treated cells reveals that suppression of inhibitory pathways is accompanied by the activation of differentiation-enhancing pathways. How significant the subtle changes we detected are to this remodeling is unknown at this time. It is possible that multiple glycocalyx options are initiated that are then refined through environmental reinforcement. Future analysis of these questions along with comparative analysis of GAG profiles induced by use of other morphogens will help to clarify the mechanisms. Such analyses combined with transcriptome, epigenome and proteome profiles will help reveal the complex circuitry regulating cell fate with environmental influences for pluripotent and differentiated cell states. We used NCCIT cells specifically because of their ability to differentiate along multiple lineages as a model for pluripotent cells, however it would be interesting to analyze pluripotent cells which have differentiated into various lineages in order to obtain pure cell populations for GAG profiling, and to compare those results to ours. As we better understand the precise contribution of GAGs to signaling pathways, such analyses will be critical to predict, track and drive cell fate. This capability is important not only for in vivo cell-based therapies, but also in vitro to improve the artificial cell environment in order to promote cell lineages as well as assembly of more complex multidimensional tissue and organ structures [41] .
Materials and methods
NCCIT cell culture and RA treatment
Teratocarcinoma cell line NCCIT (ATCC, Manassas, VA) was grown in RPMI-1640 medium (Mediatech, Manassas, VA) containing 10 % fetal bovine serum (Life Technologies, Grand Island, NY) and 100 U/mL penicillin and streptomycin (Invitrogen) and cultured at 37°C in a humidified atmosphere with 5 % CO 2 . NCCIT cell differentiation was induced by adding 10 μM trans-RA (Sigma-Aldrich, St. Louis, MO) every 3 days for up to 40 days.
Total RNA isolation, cDNA synthesis and qRT-PCR reactions Four biological replicates of untreated and RA-differentiated NCCIT cell samples were harvested after 9 and 20 days of growth, flash frozen in liquid nitrogen and stored at −80°C until use. For measurement of PG-related gene expression levels, RNA was isolated from cell lysates on day 20 of differentiation using the RNeasy Plus kit (Qiagen, Valencia, CA) and cDNA synthesis was performed using Superscript III First Strand Synthesis (Invitrogen) as previously described [42] . The qRT-PCR reactions, done in triplicate for each gene analyzed, cycling conditions and analysis of amplimer products were performed as described. Briefly, reactions contained 1.25 μL of diluted cDNA template (1:10), 1.25 μL of primer pair mix (125 μM final concentration) and 2.5 μL iQ SYBR Green Supermix (BioRad, Hercules, CA) added to 96 well microtiter plates. Primers for the control gene, β-actin (NM 001101), were included on each plate to control for run variation and to normalize individual gene expression. Primer pairs for GAG-related genes were designed within a single exon [43, 44] and primer design validation done previously using the standard curve method [43, 45] . Primer sequences and accession numbers for genes can be found in Supplemental Table 1 .
Calculation of relative gene expression levels and statistical analysis
An average of the triplicate Ct values for each gene was determined and the standard deviation calculated. Samples were rerun if the acceptable standard deviation value of >0.5 Isolation and purification of total and cell surface GAGs
For total GAG recovery, 1×10 8 pluripotent NCCIT and RAdifferentiated cells were harvested at the indicated time points, washed in PBS three times, and centrifuged to pellet cells. Isolation and purification of GAGs was performed as previously described with some modifications [42, 46] . Specifically, cell pellets were resuspended in 1 mL water and subjected to proteolysis at 55°C in 2 mg/mL actinase E (Kaken Biochemicals, Tokyo, Japan) for 20 h. After proteolysis, particulates were removed by using a 0.22 μm syringe-top filter. Peptides were removed from the samples using Microcon Centrifugal Filter Units YM-10 (10 k MWCO, 15 mL, Vivascience, Ridgewood, NJ). Samples were collected from the top layer of the filtration membrane and lyophilized, then dissolved in 8 M urea containing 2 % CHAPS (pH8.3, Sigma-Aldrich). A Vivapure MINI Q H spin column was prepared by equilibrating with 200 μL of 8 M urea containing 2 % CHAPS (pH8.3). The clarified, filtered samples were loaded onto and run through an equilibrated Vivapure MINI Q H spin column at 700×g. The columns were first washed with 200 μL of 8 M urea containing 2 % CHAPS at pH8.3, then washed five times with 200 μL 200 mM NaCl. GAGs were released from the spin column by washing three times with 100 μL of 16 % NaCl, and desalted with a Microcon Centrifugal Filter Unit YM-3 (3,000 MWCO, Millipore, Billerica, MA) spin column. The isolated GAG samples were freeze-dried for future analysis.
Enzymatic depolymerization of GAGs for CS/DS and HP/ HS analysis
Isolated GAG samples were incubated with chondroitin lyase ABC (10 m-units, Seikagaku Corporation, Tokyo, Japan) and chondroitin lyase ACII (5 m-units, Seikagaku Corporation) at 37°C for 10 h and the enzymatic products were recovered by centrifugal filtration as described above but at 13,000×g. CS/ DS disaccharides that passed through the filter were freezedried for LC-MS analysis. GAGs remaining in the retentate were collected by reversing the filter and spinning at 13,000× g, followed by incubation with 10 m-units of heparin lyase I, II, and III at 37°C for 10 h. The products were recovered by centrifugal filtration and the HP/HS disaccharides collected and freeze-dried for LC-MS analysis. Cloning, E. coli expression and purification of the recombinant heparin lyase I (EC 4.2.2.7), heparin lyase II (no EC assigned), and heparin lyase III (EC 4.2.2.8) from F. heparinum were performed as previously described in our lab [16, 47, 48] .
LC-MS disaccharide composition analysis of CS/DS and HP/HS
LC-MS analyses were performed on an Agilent 1200 LC/ MSD instrument (Agilent Technologies, Inc. Wilmington, DE) equipped with a 6300 ion trap with two separate systems for the CS/DS disaccharide analysis and HP/HS disaccharide analysis. Unsaturated disaccharide standards of CS/ DS, Δ4-GlcA-GalNAc (0S), Δ4-GlcA-GalNAc4S (4S), Δ4-GlcA-GalNAc6S (6S), Δ4-GlcA2S-GalNAc (2S), Δ4-GlcA2S-GalNAc4S (2S4S), Δ4-GlcA2S-GalNAc6S (2S6S), Δ4-GlcA-GalNAc4S6S (4S6S), Δ4-GlcA2S-GalNAc4S6S (2S4S6S) and unsaturated disaccharide standards of HP/HS, Δ4-GlcA-GlcNAc (0S), Δ4-GlcA-GlcNS (NS), Δ4-GlcA-GlcNAc6S (6S), Δ4-GlcA2S-GlcNAc (2S), Δ4-GlcA2S-GlcNS (NS2S), Δ4-GlcA-GlcNS6S (NS6S), Δ4-GlcA2S-GlcNAc6S (2S6S), Δ4-GlcA2S-GlcNS6S (NS2S6S) were obtained from Seikagaku America-NorthStar BioProducts (East Falmouth, MA) and Iduron (Manchester, UK). The column used was a 1.7 μm Acquity UPLC BEH C18 column (2.1×150 mm, Waters, Milford, MA). For CS/DS disaccharide analysis, solutions A and B for UPLC were 0 and 75 % acetonitrile, respectively, containing the same concentration of 15 mM HXA as an ion-pairing reagent and 100 mM HFIP as an organic modifier. The column temperature was maintained at 45°C. For disaccharide analysis, solution A was used for 10 min, followed by a linear gradient from 10 to 40 min of 0 to 50 % (v/v) solution B at the flow rate of 100 μL/min. The electrospray interface was set in positive ionization mode with the skimmer potential 40.0 V, capillary exit 40.0 V, with the temperature set at 350°C to obtain maximum abundance of the ions in a full-scan spectra (350-1,500 Da, 10 full scans/s) [49] . Nitrogen was used as a drying gas (8 L/min) and a nebulizing gas (40 psi). For HP/HS disaccharide analysis, eluent A was water/acetonitrile (85:15) v/v, and eluent B was water/acetonitrile (35:65) v/v. Both eluents contained 12 mM tributylamine (TrBA) and 38 mM NH 4 OAc with pH adjusted to 6.5 with acetic acid. The column temperature was maintained at 45°C. For disaccharide analysis, solution A was used for 10 min, followed by a linear gradient from 10 to 40 min of 0 to 50 % (v/v) solution B at the flow rate of 100 μL/min. The electrospray interface was set in negative ionization mode with the skimmer potential and capillary exit of −40.0 V, with a temperature of 350°C to obtain maximum abundance of the ions in a full-scan spectra (350-1,500 Da, 10 full scans/s). Nitrogen was used as a drying gas (8 L/min) and nebulizing gas (40 psi) [50] .
